Immunotherapy in Hepatocellular Carcinoma

Patients with hepatocellular carcinoma (HCC) have been traditionally deprived from highly effective systemic therapy options in the past decades. The multi-targeted tyrosine kinase inhibitor sorafenib, approved in 2008, remained the only treatment option for advanced HCC for over a decade. A number...

Descripción completa

Detalles Bibliográficos
Autores principales: Fulgenzi, Claudia A. M., Talbot, Thomas, Murray, Sam M., Silletta, Marianna, Vincenzi, Bruno, Cortellini, Alessio, Pinato, David J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Upper Gastrointestinal Cancers (JD Berlin, Section Editor)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8382645/
https://www.ncbi.nlm.nih.gov/pubmed/34424422
http://dx.doi.org/10.1007/s11864-021-00886-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8382645/
https://www.ncbi.nlm.nih.gov/pubmed/34424422
http://dx.doi.org/10.1007/s11864-021-00886-5

Ejemplares similares